HAVCR2 and cancer: In the past two decades, emerging studies confirmed that the blockade of ICBs (PD-1, PD-L1, CTLA4, TIM-3, TIGIT etc.)has rapidly become the most promising anti-cancer strategies for multiple types of cancer, including GC [13, 14, 46].